drugset / Trial / NCT06563713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase 1a, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STSP-0902.
Timeline
- Start
- 2024-07-31
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STSP-0902 | Unknown | — | Subcutaneous |